Consort Medical, parent company of device maker Bespak, has reported an 84.8% increase in revenue from £100 million in FY 2014 to £184.8 million in FY 2015, an increase it attributes largely to 5.8% growth from Bespak and £79 million in revenues from CDMO Aesica, which Consort acquired in November 2014.
The company attributes good part of Bespak’s revenue growth to a 26% increase in sales of the Chiesi Nexthaler, which is manufactured at Bespak’s King’s Lynn, UK facility.
According to Consort, the acquisition of Aesica, which recently expanded its inhalation development and manufacturing capabilities, “increases the depth of customer relationships by embedding the enlarged group at multiple levels in the drug and delivery device supply chain,” and the company plans to reorganize to “further validate and realize the potential synergies and opportunities” of combining the businesses.
Read the Consort Medical press release.
